Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
Phase 1 Study of Autologous Tris-CAR-T Cell Locoregional Immunotherapy for Recurrent Glioblastoma
Beijing Tiantan Hospital
10 participants
Sep 30, 2023
INTERVENTIONAL
Conditions
Summary
This is a Phase 1 study of recurrent glioblastoma locoregional adoptive therapy with autologous peripheral blood T cells lentivirally transduced to express a dual-target, truncated IL7Ra modified chimeric antigen receptor (CAR), delivered by Ommaya reservoir, a pre-indwelled catheter in the tumor resection cavity or ventricle. Patients with pathological confirmation of glioblastoma and radiological evidence of recurrence are candidates for this clinical trial. If the patient meets all other eligibility criteria, and meets none of the exclusion criteria, will have leukapheresis, and a subsequent Ommaya reservoir implantation. T cells will be isolated from the PBMC sample and then be bioengineered into a 4th generation CAR-T cell, Tris-CAR-T cells. Recipients will be assigned to three courses in the order of enrollment. The first 2 patients will be assigned to the low-dose group. The second 2 patients will be assigned to the high dose group. The first 4 patients will have at least one dose of autologous Tris-CAR-T cells delivery via the Ommaya reservoir, at a maximum of 6 doses. The interval between the first and the second dose is 28 days, and the rest doses will be administered weekly. The last 6 patients will be assigned to the consecutive multidose group, and will receive a weekly dose of autologous Tris-CAR-T cells for a maximum of 8 weeks. All patients will undergo studies including MRI to evaluate the effect of the CAR-T cells, physical examination, and cerebrospinal fluid cytokine assays to evaluate side effects. All patients will undergo a long-term follow-up. The hypothesis is that an adequate amount of Tris-CAR-T cells can be manufactured to complete all the three courses. The other hypothesis is that Tris-CAR-T cells can safely and effectively be administered through the Ommaya reservoir to allow the CAR-T cells to directly interact with the tumor cells for each patient enrolled in the study. The primary aim of the study will be to evaluate the safety of Tris-CAR-T administration. Secondary aims of the study will include evaluating CAR-T cell distribution within cerebrospinal fluid and peripheral blood, tumor progress post-CAR-T cell infusion, and, if tissue samples from multiple time points are available, also evaluate the degree of target expression, biological characteristics of samples at diagnosis versus at recurrence or progression.
Eligibility
Inclusion Criteria18
- Age: 18 years to 70 years (including cut-off values).
- Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and residual tumor after intracranial tumor resection/biopsy performed in Beijing Tiantan Hospital.
- Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at least 4 weeks. All toxicities of prior treatment should be defined as less than or equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 5.0).
- Patients who is suitable for craniotocerebrospinal fluid shunt and attachment (Ommaya device) implantation confirmed by a competent physician.
- Patients and/or legal representative is able to sign written informed consent.
- Kanovsky Performance Status (KPS) ≥ 70.
- According to the researchers' judgment, the life expectancy ≥ 8 weeks.
- White blood cells (WBC) \> 3.50×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Platelet ≥ 200×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Blood oxygen saturation ≥ 95% (performed within 14 days prior to PBMC collection unless otherwise noted).
- Seronegative of the combination of human immunodeficiency virus (HIV) antibody (Ab) (performed within 14 days prior to PBMC collection unless otherwise noted).
- Fertile women: a negative serum pregnancy test (performed within 14 days prior to PBMC collection unless otherwise noted).
- The patient agrees that contraception should be used in patients of childbearing age for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The period of childbearing age is defined as unsurgically neutered (men and women) or without menopause for more than 1 year (women only).
Exclusion Criteria14
- Kanovsky Performance Status (KPS) ≤ 70.
- Highly allergic constitution or severe allergies history.
- Those who have psychiatric or psychological diseases and cannot cooperate with treatment and efficacy assessment.
- Receive other drug trials within 60 days before enrollment, or receive other routine treatment in non-experimental designs for glioblastoma, such as stereotactic radiation therapy or placement of carmustine wafers.
- Combined with infection, active infection, fever of unknown cause.
- Combined with serious or unstable heart, lung, liver, kidney and hematopoietic system diseases, including active hepatitis.
- Combined with inflammation and immune system diseases (such as rheumatoid arthritis), or known immunosuppressive diseases.
- Combined with neurological diseases, such as diffuse leptomeningeal disease, or neurodegenerative diseases.
- Known allergies to immunotherapy and related cellular products.
- Patients who have received any gene therapy before.
- Long-term use of immunosuppressants is required for any reason.
- Patients with a history of organ transplantation or who are waiting for organ transplantation.
- Special cases: pregnancy or lactation.
- Other circumstances in which the investigators believe the patient is unsuitable for this trial.
Interventions
Intratumoral or intraventricular administration via Ommaya reservoir. Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells. In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly. Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05577091